66211-92-5
Chemical Structure
Detorubicin
Synonym(s): NSC 292652; RP 33921
- CAS No.: 66211-92-5
- Formula:C33H39NO14
- Molecular Weight:673.67
IUPAC Name: 2-((2S,4S)-4-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-oxoethyl 2,2-diethoxyacetate
InChIKey: XZSRRNFBEIOBDA-CFNBKWCHSA-N
SMILES: OC=1C2=C([C@@H](O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C[C@@](C(COC(C(OCC)OCC)=O)=O)(O)C2)C(O)=C4C1C(=O)C=5C(C4=O)=C(OC)C=CC5
Biological Activity: Detorubicin (NSC 292652; RP 33921) is a semi-synthetic anthracycline anticancer agent and a hydrophobic prodrug of Doxorubicin (HY-15142A). Detorubicin enters cancer cells faster and achieves higher intracellular levels than Doxorubicin. Detorubicin localizes exclusively to lysosomes and the nucleus, with unmetabolized Detorubicin accumulating mainly in lysosomes. Detorubicin can be used in research related to hematologic malignancies and L1210 leukemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Detorubicin | Detorubicin (NSC 292652; RP 33921) is a semi-synthetic anthracycline anticancer agent and a hydrophobic prodrug of Doxorubicin (HY-15142A). Detorubicin enters cancer cells faster and achieves higher intracellular levels than Doxorubicin. Detorubicin localizes exclusively to lysosomes and the nucleus, with unmetabolized Detorubicin accumulating mainly in lysosomes. Detorubicin can be used in research related to hematologic malignancies and L1210 leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Deprez-de Campeneere D, et al.. Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice. Cancer chemotherapy and pharmacology. 1982;8(2):193-7. [Content Brief]
- [2]. Zenebergh A, et al.. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells. European journal of cancer & clinical oncology. 1984 Jan;20(1):115-21. [Content Brief]
Keywords
